Position in MYGN
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$40,003,393
-$54,115,276 QoQ
Shares Held
8,889,644
-41.9% QoQ
Ownership
9.41%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 97%
Shared 0%
None 3%
Common Shares in MYGN Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026BlackRock, Inc. holds $53,866,454,003 across 42 Diagnostics & Research names. MYGN ranks #30 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
30,427,192 | $14,955,877,673 | |
| 2 | DHR |
Danaher Corp /De/
|
51,640,619 | $9,791,061,354 | |
| 3 | IDXX |
Idexx Laboratories Inc /De
|
8,365,553 | $4,700,520,563 | |
| 4 | A |
Agilent Technologies, Inc.
|
25,902,662 | $2,952,385,405 | |
| 5 | IQV |
Iqvia Holdings Inc.
|
15,027,444 | $2,562,780,290 | |
| 6 | WAT |
Waters Corp /De/
|
8,543,014 | $2,544,109,560 | |
| 7 | ILMN |
Illumina, Inc.
|
19,023,590 | $2,344,847,691 | |
| 8 | MTD |
Mettler Toledo International Inc/
|
1,771,002 | $2,233,587,712 |
All Filings in MYGN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $40,003,393 | 8,889,644 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $94,118,669 | 15,303,850 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $107,578,250 | 14,879,427 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $80,033,686 | 15,072,259 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $137,114,012 | 15,458,176 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $218,093,092 | 15,907,593 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $422,965,657 | 15,442,339 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||